Immumed, Inc.

ImmuMed, Inc. is a development-stage biotechnology company founded to develop and market innovative therapeutic compounds that modify the human immune response to prevent or treat life-threatening disease. Currently, the Company focuses on commercializing polyclonal antibodies for adjuvant therapies, which is the administration of antibodies in conjunction with standard therapies in order to improve a patient’s outcome. In favor of pursuing curative products, many large pharmaceutical companies have abandoned the area of adjuvant antibodies, allowing smaller companies, such as ImmuMed, to capitalize on opportunities within this segment.  The website can be viewed at

Leave a Reply

Your email address will not be published. Required fields are marked *